Ultragenyx Pharmaceutical Inc.
For the period ended Dec 31, 2025. Filed Feb 18, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 18, 2026
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in millions, except per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $421 | $174 |
| Marketable securities | 259 | 436 |
| Accounts receivable, net | 158 | 122 |
| Inventory | 52 | 45 |
| Prepaid expenses and other assets | 61 | 40 |
| Total current assets | 951 | 817 |
| Property, plant, and equipment, net | 244 | 266 |
| Marketable securities | 57 | 135 |
| Intangible assets, net | 176 | 178 |
| Goodwill | 44 | 44 |
| Other assets | 60 | 63 |
| Total assets | $1,532 | $1,503 |
| LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $31 | $39 |
| Accrued liabilities | 265 | 241 |
| Lease liabilities | 12 | 10 |
| Liabilities for sales of future royalties | 69 | 50 |
| Other liabilities | 7 | 4 |
| Total current liabilities | 384 | 344 |
| Lease liabilities | 24 | 30 |
| Deferred tax liabilities | 30 | 30 |
| Liabilities for sales of future royalties | 1,147 | 820 |
| Other liabilities | 20 | 17 |
| Total liabilities | 1,605 | 1,241 |
| Commitments and contingencies (Note 15) | ||
| Noncontrolling interest | 7 | 7 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, par value of $0.001 per share—25.0 shares authorized; nil outstanding in 2025 and in 2024 | — | — |
| Common stock, par value of $0.001 per share—250.0 shares authorized; outstanding—96.6 in 2025 and 92.5 in 2024 | — | — |
| Treasury stock, at cost, 0.2 shares in 2025 and 0.1 shares in 2024 | (8) | (4) |
| Deferred compensation obligation | 8 | 4 |
| Additional paid-in capital | 4,451 | 4,213 |
| Accumulated other comprehensive income (loss) | 1 | (1) |
| Accumulated deficit | (4,532) | (3,957) |
| Total stockholders’ equity (deficit) | (80) | 255 |
| Total liabilities, noncontrolling interest and stockholders’ equity (deficit) | $1,532 | $1,503 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.